Amgen Inc. (AMGN) FY2024 Q3 P&L / Income Statement

Amgen Inc. (AMGN) FY2024 Q3 P&L / Income Statement

Income statement for 2024-07-01 through 2024-09-30. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

8,503,000,000 US dollars

Cost of sales

3,310,000,000 US dollars

Gross profit (calculated)

5,193,000,000 US dollars

Operating expenses (calculated)

3,146,000,000 US dollars

Operating income

2,047,000,000 US dollars

Other income (expense), net (calculated)

1,054,000,000 US dollars

Income before income taxes

3,101,000,000 US dollars

Provision for income taxes

271,000,000 US dollars

Net income

2,830,000,000 US dollars

Prolia

1,045,000,000 US dollars

ENBREL

825,000,000 US dollars

XGEVA

541,000,000 US dollars

Repatha

567,000,000 US dollars

Otezla

564,000,000 US dollars

TEPEZZA

488,000,000 US dollars

EVENITY

399,000,000 US dollars

Kyprolis

378,000,000 US dollars

Nplate

456,000,000 US dollars

Aranesp

337,000,000 US dollars

KRYSTEXXA

310,000,000 US dollars

BLINCYTO

327,000,000 US dollars

Vectibix

282,000,000 US dollars

TEZSPIRE

269,000,000 US dollars

Other products

1,363,000,000 US dollars

Other revenues

352,000,000 US dollars

Research and development

1,450,000,000 US dollars

Selling, general and administrative

1,625,000,000 US dollars

Other

71,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.